HeimGSK • NYSE
add
GSK plc
Við síðustu lokun
58,07 $
Dagbil
58,33 $ - 59,36 $
Árabil
32,38 $ - 61,70 $
Markaðsvirði
121,61 ma. USD
Meðalmagn
6,51 m.
V/H-hlutf.
15,76
A/V-hlutfall
3,02%
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (GBP) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 8,62 ma. | 6,17% |
Rekstrarkostnaður | 4,57 ma. | -0,28% |
Nettótekjur | 636,00 m. | 53,62% |
Hagnaðarhlutfall | 7,38 | 44,71% |
Hagnaður á hvern hlut | — | — |
EBITDA | 2,50 ma. | 35,38% |
Virkt skatthlutfall | 23,47% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (GBP) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 3,41 ma. | -21,27% |
Heildareignir | 61,12 ma. | 2,78% |
Heildarskuldir | 45,16 ma. | -2,62% |
Eigið fé alls | 15,96 ma. | — |
Útistandandi hlutabréf | 4,01 ma. | — |
Eiginfjárgengi | 14,23 | — |
Arðsemi eigna | 5,87% | — |
Ávöxtun eigin fjár | 10,70% | — |
Peningaflæði
Breyting á handbæru fé
| (GBP) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 636,00 m. | 53,62% |
Handbært fé frá rekstri | 2,28 ma. | -2,19% |
Reiðufé frá fjárfestingum | -933,00 m. | 16,62% |
Reiðufé frá fjármögnun | -856,00 m. | -1,66% |
Breyting á handbæru fé | 448,00 m. | 19,47% |
Frjálst peningaflæði | 1,15 ma. | -49,69% |
Um
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Framkvæmdastjóri
Stofnsett
27. des. 2000
Vefsvæði
Starfsfólk
68.629
